Avista Healthcare Partners and Damier Group to Acquire sanotact Group

Avista Healthcare Partners, a New York-based private equity firm specializing in healthcare investments, together with Belgium’s Damier Group, have signed a definitive agreement to acquire sanotact Group GmbH, a leading German developer and manufacturer of vitamins, minerals, and supplements (VMS). The transaction, announced on May 22, 2026, marks a strategic expansion into the European consumer health market.

Sanotact operates a diversified business model that combines a full-service contract development and manufacturing organization (CDMO) platform with a portfolio of branded VMS products, including its flagship sanotact® brand. Headquartered in Münster, Germany, the company serves drugstore and distribution customers across 80 international markets, leveraging its broad product capabilities and reputation for high-quality manufacturing.

The financial terms of the deal were not disclosed. Existing shareholder FLOTTE Beteiligungen GmbH will reinvest alongside the new investors, maintaining a significant stake in the company. The transaction remains subject to regulatory approval.

Avista Healthcare Partners, founded in 2005, manages over $10 billion in healthcare investments globally, focusing on growth-oriented businesses with strong management and scalable models. Damier Group, a family office led by entrepreneur Yvan Vindevogel, specializes in European consumer healthcare platforms aligned with long-term health trends.

Thompson Dean, Chairman of Avista, highlighted sanotact’s position as a premier independent VMS platform in Europe, citing strong secular growth drivers such as increasing consumer focus on preventative health. “Sanotact’s differentiated capabilities, strong innovation engine, and established market position provide a solid foundation to drive robust growth,” Dean said.

Yvan Vindevogel, Founder of Damier Group, emphasized the alignment with Damier’s investment philosophy, noting the accelerating shift toward self-care in Europe. He praised sanotact’s leadership under CEO Martin Spengler for consistently delivering strong financial results and strategic execution.

Sanotact’s CEO, Martin Spengler, expressed enthusiasm about partnering with Avista, Damier, and FLOTTE to enhance innovation capabilities, expand international presence, and continue delivering high-quality products.

The acquisition is expected to generate multiple synergies, including cross-selling sanotact’s branded products to Avista’s healthcare portfolio, expanding distribution channels, and leveraging sanotact’s CDMO platform to improve manufacturing scale and efficiency. Cost optimization through consolidated supply chains and shared R&D resources is also anticipated.

Industry experts note that this deal strengthens sanotact’s position as a leading independent VMS platform in Europe, intensifying competitive pressure on other manufacturers and CDMOs. The transaction reflects broader consolidation trends in the consumer health and pharmaceutical manufacturing sectors, driven by rising demand for preventative health products and innovation acceleration.

Advisors on the deal include Alantra as exclusive M&A advisor to FLOTTE, with CMS and White & Case providing legal counsel to the respective parties.

Looking ahead, the new ownership group plans to focus on integrating operational processes, maintaining product quality and regulatory compliance, and retaining key talent to realize growth and innovation objectives. The partnership aims to capitalize on evolving consumer health trends and expand sanotact’s footprint across international markets.